Advanced search
Start date

Search for markers associated with the antibody response against erythrocyte antigens after transfusion in patients with myelodysplastic syndromes


Blood transfusion is a vital therapy in treating and preventing the complications of myelodysplastic syndromes (MDS). Although transfusions of packed red blood cells significantly improve quality of life in this patient population, their use is limited due to the high incidence of alloimunization, a serious complication in patients with MDS that can result in Delayed Hemolytic Transfusion Reaction (DHTR). However not all patients develop antibodies after exposure to RBC transfusion. The hypothesis is that patient's alloimmunized to erythrocyte antigens represent a genetically distinct group with an increased susceptibility to sensitization to blood group antigens. Studies have shown that the process of alloimunization to blood group antigens is under control of genetic and acquired factors, although the relative importance of these factors for alloimunization in MDS patients has not been elucidated. Pre transfusion tests that can help to predict in advance which patients will develop alloantibodies to erythrocyte antigens need to be developed. Our aim is to identify markers that are associated to MDS patients susceptibility to erythrocyte alloimmunization, by analyzing class I and II Human Leukocyte Antigens (HLA), T helper cell phenotypes and regulatory T cells (Tregs), and single nucleotide polymorphisms in cytokine genes relevant to humoral immunity in alloimmunized and non-alloimmunized MDS patients and in normal blood donors as controls.. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list by writing to: